Trial reportNature medicine2025
Glecirasib in KRAS
Abstract readClinical Trial, Phase IClinical Trial, Phase IIMulticenter Study
In one paragraph
Trial report in Nature medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Efficacy and safety of glecirasib in solid tumors with KRAS G12C mutation: A pooled analysis of two phase I/II trials.Cancer communications (London, England) · 2025Trial
- D3S-001 in advanced solid tumors with KRASNature medicine · 2025Trial
- Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation.Signal transduction and targeted therapy · 2025Trial
- Antitumor Activity of a Synthetic Small RNA Based on aInternational journal of molecular sciences · 2026Article
- Precision Targeting ofInternational journal of molecular sciences · 2026Review
- MXD4 enhances resistance to KRAS G12C-targeted therapy in lung adenocarcinoma by suppressing ACSL4-mediated ferroptosis.Respiratory research · 2026Article
- Small-molecule degraders for oncogenic KRASNature communications · 2026Article
- Systematic and precise interventions for KRAS-mutant cancers.Experimental hematology & oncology · 2026Review
- Non-small cell lung cancer research: advances and persistent challenges.Frontiers in oncology · 2026Review
- Evolution of direct RAS inhibitors: from undruggable target to clinical breakthroughs.Molecular cancer · 2025Review
- Lighting the path against cancer with academic light: Forty years of growth with the Chinese Medical Association-Celebrating the 110th anniversary of the founding of the Chinese Medical Association.Cancer pathogenesis and therapy · 2025Article
- [Advances in Diagnosis and Targeted Therapy of KRASG12C Mutant Non-small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025Review
- Literature review of advances and challenges inTranslational lung cancer research · 2025Review
- Differential Response and Resistance to KRAS-Targeted Therapy.Molecular carcinogenesis · 2025Review
- Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 Inhibitor JAB-3312.Cancer research communications · 2025Article
- Emerging Targets in Non-Small Cell Lung Cancer.Lung Cancer (Auckland, N.Z.) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
49 authors.
Yuankai ShiDepartment of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. syuankai@cicams.ac.cn.ORCID http://orcid.org/0000-0002-8685-6744
Jian FangBeijing Cancer Hospital, Beijing, China.
Ligang XingShandong Cancer Hospital, Jinan, China.
Yu YaoThe First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Jian ZhangFudan University Shanghai Cancer Center, Shanghai, China.
Lian LiuQilu Hospital of Shandong University, Jinan, China.
Yongsheng WangWest China Hospital of Sichuan University, Chengdu, China.
Changlu HuAnhui Provincial Cancer Hospital, Hefei, China.
Jianping XiongThe First Affiliated Hospital of Nanchang University, Nanchang, China.
Zhihua LiuJiangxi Cancer Hospital, Nanchang, China.
Runxiang YangYunnan Cancer Hospital, Kunming, China.
Zhen WangLinyi Cancer Hospital, Linyi, China.
Enfeng ZhaoCangzhou Hospital of Integrated Traditional Chinese and Western Medicine of Hebei Province, Cangzhou, China.
Mengzhao WangPeking Union Medical College Hospital, Beijing, China.
Yanqiu ZhaoHenan Cancer Hospital, Zhengzhou, China.
Kejing TangThe First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Zhihua LiSun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
Zhengbo SongZhejiang Cancer Hospital, Hangzhou, China.
Yongsheng LiChongqing Cancer Hospital, Chongqing, China.ORCID http://orcid.org/0000-0003-2175-9449
Wu ZhuangFujian Cancer Hospital, Fuzhou, China.
Bo JinThe First Affiliated Hospital of China Medical University, Shenyang, China.
Ying ChengJilin Cancer Hospital, Changchun, China.
Yanping HuHubei Cancer Hospital, Wuhan, China.
Yanhong GuJiangsu Province Hospital, Nanjing, China.
Lin WuHunan Cancer Hospital, Changsha, China.ORCID http://orcid.org/0000-0001-7078-7767
Rui MaLiaoning Cancer Hospital & Institute, Shenyang, China.
Qitao YuGuangxi Medical University Cancer Hospital, Nanning, China.
Yan YuHarbin Medical University Cancer Hospital, Harbin, China.
Jun ZhaoBeijing Cancer Hospital, Beijing, China.ORCID http://orcid.org/0000-0003-1464-7158
Hui ZhaoThe Second Hospital of Anhui Medical University, Hefei, China.
Dongqing LvTaizhou Hospital of Zhejiang Province, Taizhou, China.
Yanhong ShangAffiliated Hospital of Hebei University, Baoding, China.
Puyuan XingDepartment of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Jin ZhouSichuan Cancer Hospital, Chengdu, China.
Xingya LiThe First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Zhe LiuBeijing Chest Hospital Affiliated to Capital Medical University, Beijing, China.ORCID http://orcid.org/0000-0002-2691-7488
Zhaoxia DaiThe Second Hospital of Dalian Medical University, Dalian, China.ORCID http://orcid.org/0000-0003-1578-4437
Guohao XiaJiangsu Cancer Hospital, Nanjing, China.
Xueqin ChenHangzhou Cancer Hospital, Hangzhou, China.
Yi BaTianjin Medical University Cancer Institute & Hospital, Tianjin, China.
Chunmei BaiPeking Union Medical College Hospital, Beijing, China.
Qingshan LiAffiliated Hospital of Chengde Medical University, Chengde, China.
Guangyu AnAffiliated Beijing Chaoyang Hospital of Capital Medical University, Beijing, China.
Weiguo HuRenmin Hospital of Wuhan University, Wuhan, China.
Yinxiang WangJacobio Pharmaceuticals Co., Ltd., Beijing, China.
Andrea Wang-GillamJacobio (US) Pharmaceuticals, Inc., Burlington, MA, USA.
Yuli DingJacobio Pharmaceuticals Co., Ltd., Beijing, China.
Qiao LiJacobio Pharmaceuticals Co., Ltd., Beijing, China.
Zhiyue RaoJacobio Pharmaceuticals Co., Ltd., Beijing, China.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glecirasib (JAB-21822) is a new covalent oral KRAS-G12C inhibitor. This multicenter, single-arm phase 2b study assessed the efficacy and safety of glecirasib administered orally at 800 mg daily in patients with locally advanced or metastatic KRAS
Indexed as
Carcinoma, Non-Small-Cell LungLung NeoplasmsMutationProto-Oncogene Proteins p21(ras)AdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedKRAS protein, humanProto-Oncogene Proteins p21(ras)
Identifiers
PMID
39762419What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.